Urapidil, compared to nitroglycerin, has better clinical safety in the treatment of hypertensive patients with acute heart failure: a meta-analysis

References

• McmurrayJJPetrieMCMurdochDRDavieAPClinical epidemiology of heart failure: public and private health burdenEur Heart J199819Suppl PP9P169886707
   PubMed Web of Science ®Google Scholar
• AdamsKFFonarowGCEmermanCLCharacteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)Am Heart J2005149220921615846257
   PubMed Web of Science ®Google Scholar
• UchmanowiczIJankowska-PolańskaBMazurGSivarajan FroelicherECognitive deficits and self-care behaviors in elderly adults with heart failureClin Interv Aging2017121565157229042757
   PubMed Web of Science ®Google Scholar
• WajnerAZuchinaliPOlsenVPolanczykCARohdeLECauses and predictors of in-hospital mortality in patients admitted with or for heart failure at a tertiary hospital in BrazilArq Bras Cardiol2017109432133028977049
   PubMed Web of Science ®Google Scholar
• HornPKelmMWestenfeldRIntegration of medical therapy and mechanical circulatory support in the management of acute heart failureArch Med Sci20166613171323
   Web of Science ®Google Scholar
• AlexanderPAlkhawamLCurryJLack of evidence for intravenous vasodilators in ED patients with acute heart failure: a systematic reviewAm J Emerg Med201533213314125530194
   PubMed Web of Science ®Google Scholar
• RudigerAHarjolaVPMüllerAAcute heart failure: clinical presentation, one-year mortality and prognostic factorsEur J Heart Fail20057466267015921809
   PubMed Web of Science ®Google Scholar
• PonikowskiPVoorsAAAnkerSDESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESCEur Heart J201637272129220027206819
   PubMed Web of Science ®Google Scholar
• DarlingCEElisabeth SunJGoldbergJA historical perspective on presentations of hypertensive acute heart failureJ Cardiovasc Dis Diagn2017050323299517
   Google Scholar
• LevyPDLaribiSMebazaaAVasodilators in acute heart failure: review of the latest studiesCurr Emerg Hosp Med Rep20142212613224855585
   PubMedGoogle Scholar
• HunterBRMartindaleJAbdel-HafezOPangPSApproach to acute heart failure in the emergency departmentProg Cardiovasc Dis201760217818628865801
   PubMed Web of Science ®Google Scholar
• ViauDMSala-MercadoJASprangerMDO’LearyDSLevyPDThe pathophysiology of hypertensive acute heart failureHeart2015101231861186726123135
   PubMed Web of Science ®Google Scholar
• Writing Committee Members; YancyCWJessupM2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelinesCirculation201312816e240e32723741058
   PubMed Web of Science ®Google Scholar
• den UilCABrugtsJJImpact of intravenous nitroglycerin in the management of acute decompensated heart failureCurr Heart Fail Rep2015121879325301529
   PubMedGoogle Scholar
• ElkayamUBitarFAkhterMWKhanSPatrusSDerakhshaniMIntravenous nitroglycerin in the treatment of decompensated heart failure: potential benefits and limitationsJ Cardiovasc Pharmacol Ther20049422724115678242
   PubMed Web of Science ®Google Scholar
• SaxenaPRVillalónCMBrain 5-HT1A receptor agonism: a novel mechanism for antihypertensive actionTrends Pharmacol Sci199011395962104465
   PubMed Web of Science ®Google Scholar
• BoppCAugerCDiemunschPSchini-KerthVThe effect of urapidil, an alpha-1 adrenoceptor antagonist and a 5-HT1A agonist, on the vascular tone of the porcine coronary and pulmonary arteries, the rat aorta and the human pulmonary arteryEur J Pharmacol2016779535826957055
   PubMed Web of Science ®Google Scholar
• GrossGHanftGRugevicsC5-Methyl-urapidil discriminates between subtypes of the alpha 1-adrenoceptorEur J Pharmacol198815123333352901974
   PubMed Web of Science ®Google Scholar
• van ZwietenPABruningTAComparison of the hemodynamic effects of urapidil and flesinoxan in healthy volunteersBlood Press Suppl1994419247804508
   PubMedGoogle Scholar
• Alijotas-ReigJBove-FarreIde Cabo-FrancesFAngles-CollREffectiveness and safety of prehospital urapidil for hypertensive emergenciesAm J Emerg Med200119213013311239257
   PubMed Web of Science ®Google Scholar
• HirschlMMBinderMBurASafety and efficacy of urapidil and sodium nitroprusside in the treatment of hypertensive emergenciesIntensive Care Med19972388858889310807
   PubMed Web of Science ®Google Scholar
• ShiJLiAWeiZKetamine versus ketamine pluses atropine for pediatric sedation: a meta-analysisAm J Emerg Med20183671280128629656945
   PubMed Web of Science ®Google Scholar
• YangWZhouYJFuYA multicenter, randomized, trial comparing urapidil and nitroglycerin in multifactor heart failure in the elderlyAm J Med Sci2015350210911526164864
   PubMed Web of Science ®Google Scholar
• YangWZhouYJFuYEfficacy and safety of intravenous urapidil for older hypertensive patients with acute heart failure: a multicenter randomized controlled trialYonsei Med J201758110511327873502
   PubMed Web of Science ®Google Scholar
• ElkayamUJanmohamedMHabibMHatamizadehPVasodilators in the management of acute heart failureCrit Care Med2008361 SupplS95S10518158484
   PubMedGoogle Scholar
• FungHLPharmacokinetic determinants of nitrate actionAm J Med1984766A2226
   PubMed Web of Science ®Google Scholar
• ElkayamUKulickDMcintoshNRothAHsuehWRahimtoolaSHIncidence of early tolerance to hemodynamic effects of continuous infusion of nitroglycerin in patients with coronary artery disease and heart failureCirculation19877635775843113764
   PubMed Web of Science ®Google Scholar
• BuchJUrapidil, a dual-acting antihypertensive agent: current usage considerationsAdv Ther201027742644320652659
   PubMed Web of Science ®Google Scholar
• VermeirenGLMalbrainMLWalpotJMCardiac ultrasonography in the critical care setting: a practical approach to assess cardiac function and preload for the “non-cardiologist”Anestezjol Intens Ter201547Specs89s104
   Google Scholar
• OrenSTurkotSParanEFlandraOSlezakLHofBEfficacy and tolerability of slow release urapidil (ebrantil) in hypertensive patients with non-insulin dependent diabetes mellitus (NIDDM)J Hum Hypertens19961021231278867567
   PubMed Web of Science ®Google Scholar
• IttnerKPZimmermannMBucherMThe effect of urapidil and ramipril on hyperglycemia in streptozotocin diabetic ratsNaunyn Schmiedebergs Arch Pharmacol20003611929710651153
   PubMed Web of Science ®Google Scholar
• RamageAGThe mechanism of the sympathoinhibitory action of urapidil: role of 5-HT1A receptorsBr J Pharmacol1991102499810021855130
   PubMed Web of Science ®Google Scholar
• LiHHortmannMDaiberACyclooxygenase 2-selective and nonselective nonsteroidal anti-inflammatory drugs induce oxidative stress by up-regulating vascular NADPH oxidasesJ Pharmacol Exp Ther2008326374575318550689
   PubMed Web of Science ®Google Scholar
• SeoKWParkJSTahkSJShinJHA case of acute myocardial infarction induced by selective cyclooxygenase-2 inhibitorChin Med J201713091131113228469113
   PubMed Web of Science ®Google Scholar
• HuangWFHsiaoFYWenYWTsaiYWCardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adultsClin Ther200628111827183617213003
   PubMed Web of Science ®Google Scholar